Cellular tumor antigen p53 R175H mutant peptide presented on HLA-A*02:01

The **Cellular tumor antigen p53 R175H mutant peptide presented on HLA-A*02:01** refers to a specific complex formed when a short peptide (typically amino acids 168–176, sequence HMTEVVRHC) derived from tumor cells bearing the R175H mutation in the TP53 gene is processed and presented on the cell surface by the major histocompatibility complex (MHC) class I molecule HLA-A*02:01[1][3][5]. This mutant p53 peptide represents a neoantigen—an abnormal peptide unique to cancer cells—that can be specifically recognized by T cells, thereby making it a highly attractive immunotherapy target[1][5][7]. The HLA-A*02:01 molecule acts as a platform for presenting this peptide on the tumor cell surface, enabling recognition by engineered T-cell receptors (TCRs) or bispecific molecules (e.g., CLSP-1025) that redirect immune effectors specifically to tumor cells expressing both TP53 R175H and HLA-A*02:01[5][7]. This strategy is under active clinical investigation for cancers harboring the R175H p53 mutation and HLA-A*02:01[9].

Other names

p53 R175H neoantigen presented on HLA-A*02:01mutant p53 (R175H) peptide-HLA-A*02:01 complexHLA-A*02:01/p53 R175H complex

Redirected T cell killing: Bispecific T-cell engagers (such as CLSP-1025) bind the p53 R175H/HLA-A*02:01 complex on tumor cells and CD3 on T cells, triggering cytotoxic T cell activity specifically against tumor cells expressing the mutant peptide[1][5][7].